DrugBiological
Tositumomab I-131 clinical trials
Also written Iodine-131 Anti-B1 Antibody and Bexxar.
How studies write it
Studies that test it under each name
Brand
Other names
Combined with it in one product
Studies by the year they started
21 studies that test it; most in 2007 (5)
| Year | Studies |
|---|---|
| 1995 | 1 |
| 1996 | 2 |
| 1998 | 4 |
| 1999 | 3 |
| 2000 | 2 |
| 2003 | 1 |
| 2004 | 2 |
| 2005 | 1 |
| 2007 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 16 · Other 7
GlaxoSmithKline (10) · Corixa Corporation (6) · University of Michigan Rogel Cancer Center (1) · Fred Hutchinson Cancer Center (1) · Susan Knox (1) · University of Pennsylvania (1) · Rush University Medical Center (1) · Stanford University (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- A conjugate made from Tositumomab source
Studies
Open first, then newest update. How each study uses tositumomab I-131 is read from its arms, and is right about nine times in ten.
Testing it · 23
- Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple MyelomaCompletedPhase 2University of Michigan Rogel Cancer CenterNCT00135200Written as Iodine I 131 Tositumomab
- A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's LymphomaTerminatedPhase 2Rush University Medical CenterNCT00479167Written as Bortezomib and Tositumomab I-131
- Tositumomab and Iodine I 131 Tositumomab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First RemissionCompletedPhase 2Fred Hutchinson Cancer CenterNCT00476047Written as Tositumomab and Iodine I 131 Tositumomab
- Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Non Hodgkin's Lymphoma (NHL) Patients With Greater Than 25% Bone Marrow InvolvementCompletedPhase 1GlaxoSmithKlineNCT00992758Written as Iodine-131 Anti-B1 Antibody
- Phase 2 Study of Bexxar in Relapsed/Refractory DLCLCompletedPhase 2Susan KnoxNCT00490009Written as Bexxar
- Study of Bexxar <Tositumomab> Combined With External Beam Radiation TherapyTerminatedPhase 2Stanford UniversityNCT00490490Written as Bexxar (tositumomab)
- Study of Safety and Efficacy of a Sequential Regimen Consisting of Three Cycles of Fludarabine Followed by Tositumomab and Iodine I 131 TositumomabCompletedPhase 2GlaxoSmithKlineNCT00933335Written as Tositumomab and Iodine I 131 Tositumomab
- Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive HistologyCompletedPhase 2GlaxoSmithKlineNCT00950755Written as tositumomab and Iodine I 131 tositumomab (anti-B1 antibody)
- Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab) for Previously Untreated, Advanced-stage, Low Grade Non-Hodgkin's LymphomaCompletedPhase 2GlaxoSmithKlineNCT00996996Written as Tositumomab and Iodine I 131 Tositumomab (Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody)
- Iodine-131 Anti-B1 Antibody Consolidation for Patients With Non-Hodgkin's Lymphoma Following First-line CHOPCompletedPhase 2GlaxoSmithKlineNCT01868035Written as tositumomab and iodine I-131 tositumomab
- Retreatment of Patients With Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti B1 AntibodyCompletedPhase 2GlaxoSmithKlineNCT00938041Written as Tositumomab and Iodine I 131 Tositumomab
- Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins LymphomaCompletedPhase 3GlaxoSmithKlineNCT00268983Written as Tositumomab and Iodine I 131 Tositumomab
- Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-refractory Low-grade or Transformed Low-grade B-cell Non-Hodgkin's LymphomaCompletedPhase 2GlaxoSmithKlineNCT00989664Written as Tositumomab and Iodine I 131 Tositumomab
- Dosimetry/Validation Study of 131Iodine-Anti B1 (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas That Have Transformed to Higher Grade HistologiesCompletedPhase 2GlaxoSmithKlineNCT01224821Written as Tositumomab (Anti-B1 Antibody) and Iodine-131 Tositumomab
- Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous TransplantCompletedPhase 1University of PennsylvaniaNCT00434629Written as Bexxar
- Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and BexxarTerminatedPhase 2University of FloridaNCT00475332Written as Iodine I -01 Tositumomab (Bexxar)
- Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 TositumomabCompletedPhase 1/2GlaxoSmithKlineNCT00062894Written as Iodine I 131 Tositumomab
- Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell LymphomaCompletedPhase 2Corixa CorporationNCT00022945Written as Iodine-131 Anti-B1 Antibody
- Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for Chronic Lymphocytic LeukemiaStatus unknownPhase 1Corixa CorporationNCT00022880Written as Iodine-131 Anti-B1 Antibody
- Expanded Access Study of Iodine-131 Anti-B1 AntibodyStatus unknownNot applicableCorixa CorporationNCT00022958Written as Iodine-131 Anti-B1 Antibody
See all 23 studies that test tositumomab I-131 →
Given in every arm · 1 — tositumomab I-131 is usual care beside what is tested
Codes
What other systems call tositumomab I-131 · ClinicalTrials.gg INT004159
- MeSH (NLM) C119496tositumomab I-131Confirmed ClinicalTrials.gov, NLM
- UNII (FDA) K1KT5M40JCTOSITUMOMAB I-131Confirmed FDA, NLM
- RxNorm 234449One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C119496 | tositumomab I-131 | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | K1KT5M40JC | TOSITUMOMAB I-131 | Confirmed FDA, NLM |
| RxNorm | 234449 | — | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.